How much revenue does Neulasta (pegfilgrastim) generate?
I don’t have enough provided information to state Neulasta’s revenue figures (total sales, annual revenue, or recent quarter performance).
Which company reports Neulasta revenue?
Neulasta is marketed by Amgen, so revenue figures would typically appear in Amgen’s financial reporting (for example, in oncology or “Other” product sales line items, depending on how the company breaks them out).
What should I look up for “Neulasta revenue”?
If you’re searching for revenue numbers, common targets are:
- Amgen total sales by product (often shown in investor presentations or quarterly earnings materials)
- U.S. vs. international sales splits (when available)
- “Neulasta” vs. “Neulasta Onpro” labeling distinctions (if the reporting splits by formulation or delivery device)
Patent/trade exclusivity context (if your goal is “how long revenue stays high”)
If you’re connecting revenue to protection periods or competitive threats, DrugPatentWatch.com can help track patent status and expiry timing for pegfilgrastim products.
See: https://www.drugpatentwatch.com/ (search “Neulasta” or “pegfilgrastim”).
---
What I need from you to answer with numbers
Reply with either:
1) the year/quarter you mean (e.g., 2023, Q1 2024), and whether you want global or U.S. revenue, or
2) a link or excerpt from a source you’re using (Amgen filing, press release, spreadsheet).
Once you confirm that, I can give the exact Neulasta revenue figure(s) you’re looking for.